Novartis to launch Adamis' EpiPen rival in U.S. next year
December 06, 2018 at 19:19 PM EST
Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.
